Skip to main content
. 2017 Sep 21;8(56):95662–95673. doi: 10.18632/oncotarget.21175

Figure 1.

Figure 1

Progression-free survival (A) and overall survival (B) in a cohort of patients (n=28) grouped according to PTPN13 mRNA expression levels (≤ or > than the median expression level) assessed by RT/PCR.